Search

Displaying results 5591 - 5600 of 7498 in total
  1. Drug

    E-2012

    go.drugbank.com/drugs/DB05171
    Experimental

    E-2012 is a gamma secretase modulator that is being evaluated as a potential new treatment for Alzheimer's disease.

  2. Drug

    Diosmetin

    go.drugbank.com/drugs/DB11259
    Approved

    Diosmetin is an O-methylated flavone and the aglycone part of the flavonoid glycosides diosmin that occurs naturally in citrus fruits [A27231]. … Pharmacologically, diosmetin is reported to exhibit anticancer, antimicrobial, antioxidant, oestrogenic and anti-inflamatory activities [A27231]. It also acts as a weak TrkB receptor agonist [A27230].

  3. Drug

    Cannabinor

    go.drugbank.com/drugs/DB05048
    Experimental

    Cannabinor, a synthetic CB2-selective agonist, is in Phase 2 clinical testing as an analgesic.

  4. Drug

    Coltuximab ravtansine

    go.drugbank.com/drugs/DB06342
    Investigational

    Coltuximab ravtansine (SAR3419) targets CD19 and is being investigated for the treatment of acute lymphoblastic leukemia (ALL).

    Synonyms: Anti-CD19 humanized monoclonal antibody conjugated to DM4
  5. Drug

    Epratuzumab

    go.drugbank.com/drugs/DB04958
    Investigational

    Epratuzumab is a humanized monoclonal antibody derived from the murine IG2a monoclonal antibody, LL2 (EPB-2). This agent may subsequently be well matched for use in oncology and the treatment of inflammatory autoimmune disorders, such as...

  6. Drug

    SNS-032

    go.drugbank.com/drugs/DB05969
    Investigational

  7. Drug

    Zenarestat

    go.drugbank.com/drugs/DB02132
    Experimental

  8. Drug

    SGS518

    go.drugbank.com/drugs/DB05042
    Experimental

    SGS518, a novel antagonist for the 5HT6 subtype of the serotonin receptor, is being developed as a treatment for Cognitive Impairment Associated with Schizophrenia (CIAS).

  9. Drug

    Mepiprazole

    go.drugbank.com/drugs/DB09197
    Experimental

    Mepiprazole mediates a weak inhibitory action on the uptake of 5-HT on hypothalamic neurons [A7816]. Mepiprazole is marketed in Spain for the treatment of anxiety neuroses. … It acts as a 5-HT2A and α1-adrenergic receptor antagonist, and has also been shown to inhibit the reuptake and induce the release of serotonin, dopamine, and norepinephrine to varying extents.

  10. Drug

    Ivarmacitinib

    go.drugbank.com/drugs/DB16756
    Investigational

    While ivarmactinib has yet to receive marketing authorization, as of February 2022 clinical trials are ongoing or completed evaluating its use in atopic dermatitis,[L40604,L40619,L40629] ankylosing spondylitis